FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to a crystalline form of tigecycline I characterised by the fact that an X-ray picture formed by powder X-ray diffraction shows diffraction peaks at the angles of 2θ 5.2° and 11.1°, as well as a diffraction peak at the angle of 29 8.3° and a diffraction peak at the angle of 2θ 24.8°. The crystalline form of tigecycline I is used for preparing pharmaceutical formulations, for treating bacterial diseases.
EFFECT: preparing the solid crystalline form of tigecycline possessing the improved stability characteristics.
8 cl, 9 dwg, 4 tbl, 10 ex
| Title | Year | Author | Number |
|---|---|---|---|
| CRYSTALLINE MODIFICATION | 2014 |
|
RU2666368C2 |
| CRYSTALLINE FORMS OF (R)-5-[3-CHLORO-4-(2, 3-DIHYDROXYPROPOXY)BEZ[Z]ILIDEN]-2-([Z]-PROPYLIMINO)-3-o-TOLYLTHIAZOLIDIN-4-ONE | 2009 |
|
RU2519548C2 |
| SALTS AND CRYSTALLINE FORMS OF DIAZABENZOFLUORANTHENE COMPOUNDS | 2017 |
|
RU2762189C2 |
| PYRIDILAMINE FUMARATE AND ITS CRYSTALS | 2015 |
|
RU2684278C1 |
| LSD1 INHIBITOR SALT AND ITS POLYMORPHIC FORM | 2019 |
|
RU2794977C2 |
| 2-[4-(METHYLAMINOMETHYL)PHENYL]-5-FLUORO-BENZOFURAN-7-CARBOXAMIDE HYDROCHLORIDE POLYMORPHOUS, METHOD FOR ITS PRODUCTION AND APPLICATION | 2018 |
|
RU2783418C1 |
| CRYSTALLINE FORM AND SALT FORM OF A PYRIDOIMIDAZOLE COMPOUND AND A CORRESPONDING METHOD OF PRODUCING | 2019 |
|
RU2769050C1 |
| CHEMICAL METHOD | 2013 |
|
RU2644160C2 |
| MANUFACTURE OF 2-(5-BROMO-4(4-CYCLOPROPYLNAPHTHALEN-1-YL)-4H-1,2,4-TRIAZOL-3-YLTHIO)ACETIC ACID | 2013 |
|
RU2666549C2 |
| CRYSTAL FORM OF PHOSPHODIESTERASE INHIBITOR, METHOD OF ITS PREPARATION AND USE | 2020 |
|
RU2814498C2 |
